CO2022001531A2 - Método para la caracterización de polipéptidos que se unen a complejos de péptido:mhc - Google Patents

Método para la caracterización de polipéptidos que se unen a complejos de péptido:mhc

Info

Publication number
CO2022001531A2
CO2022001531A2 CONC2022/0001531A CO2022001531A CO2022001531A2 CO 2022001531 A2 CO2022001531 A2 CO 2022001531A2 CO 2022001531 A CO2022001531 A CO 2022001531A CO 2022001531 A2 CO2022001531 A2 CO 2022001531A2
Authority
CO
Colombia
Prior art keywords
peptide
polypeptides
characterization
bind
mhc complexes
Prior art date
Application number
CONC2022/0001531A
Other languages
English (en)
Inventor
Heiko Schuster
Meike Hutt
Toni Weinschenk
Sebastian Bunk
Oliver Schoor
Linus Backert
Martin Hofmann
Jens Fritsche
Felix Unverdorben
Gisela Schimmack
Florian Schwörer
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CO2022001531A2 publication Critical patent/CO2022001531A2/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención concierne a un método para la caracterización de polipéptidos que se unen a complejos de péptido:MHC, p. ej. mediante espectrometría de masas y un análisis del espacio peptídico reconocido, es decir, con el fin de identificar péptidos que puedan ser uni-dos en el contexto de su presentación por el MHC, y aquellos que no puedan serlo.
CONC2022/0001531A 2019-08-13 2022-02-15 Método para la caracterización de polipéptidos que se unen a complejos de péptido:mhc CO2022001531A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886225P 2019-08-13 2019-08-13
DE102019121834 2019-08-13
PCT/EP2020/072674 WO2021028503A1 (en) 2019-08-13 2020-08-12 Method for the characterization of peptide:mhc binding polypeptides

Publications (1)

Publication Number Publication Date
CO2022001531A2 true CO2022001531A2 (es) 2022-06-21

Family

ID=72088088

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0001531A CO2022001531A2 (es) 2019-08-13 2022-02-15 Método para la caracterización de polipéptidos que se unen a complejos de péptido:mhc

Country Status (16)

Country Link
US (1) US20210048442A1 (es)
EP (1) EP4014043A1 (es)
JP (1) JP2022547794A (es)
KR (1) KR20220044485A (es)
CN (1) CN114375397A (es)
AU (1) AU2020330717A1 (es)
BR (1) BR112022002699A2 (es)
CA (1) CA3150546A1 (es)
CL (1) CL2022000352A1 (es)
CO (1) CO2022001531A2 (es)
CR (1) CR20220065A (es)
IL (1) IL289209A (es)
MX (1) MX2022001869A (es)
PE (1) PE20220564A1 (es)
TW (1) TW202120925A (es)
WO (1) WO2021028503A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3551221T3 (pl) 2016-12-08 2022-02-28 Immatics Biotechnologies Gmbh Nowe receptory komórek t i immunoterapia z ich zastosowaniem
WO2024033332A1 (en) 2022-08-08 2024-02-15 Immatics Biotechnologies Gmbh Guided positional scanning method

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60040556D1 (de) * 1999-12-06 2008-11-27 Univ Illinois Hochaffine t-zellrezeptorproteine und verfahren
US7811828B2 (en) 2004-01-28 2010-10-12 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumuor-associated
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
AU2010358291A1 (en) 2010-07-28 2013-02-28 Immunocore Ltd T cell receptors
WO2012104843A1 (en) 2011-02-06 2012-08-09 Yeda Research And Development Co.Ltd. At The Weizmann Institute Of Science Affinity maturated t cell receptors and use thereof
GB201309469D0 (en) * 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201520592D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3440104B2 (en) 2016-04-08 2023-06-14 Adaptimmune Limited T cell receptors
EP3513189A4 (en) 2016-09-16 2020-06-17 Memorial Sloan-Kettering Cancer Center METHODS AND COMPOSITIONS FOR SCREENING T-LYMPHOCYTE EPITOPES
DE102018122546B3 (de) * 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden

Also Published As

Publication number Publication date
CN114375397A (zh) 2022-04-19
CL2022000352A1 (es) 2022-09-23
KR20220044485A (ko) 2022-04-08
TW202120925A (zh) 2021-06-01
IL289209A (en) 2022-02-01
JP2022547794A (ja) 2022-11-16
MX2022001869A (es) 2022-03-11
EP4014043A1 (en) 2022-06-22
CA3150546A1 (en) 2021-02-18
BR112022002699A2 (pt) 2022-05-31
PE20220564A1 (es) 2022-04-13
AU2020330717A1 (en) 2022-02-03
CR20220065A (es) 2022-05-04
US20210048442A1 (en) 2021-02-18
WO2021028503A8 (en) 2022-04-07
WO2021028503A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
CL2020003416A1 (es) Constructos de anticuerpo biespecificos que se unen a mesotelina y cd3 (divisional sol. 201800268)
CL2021000716A1 (es) Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269)
CL2020001854A1 (es) Anticuerpos de unión a gprc5d.
CO2022001531A2 (es) Método para la caracterización de polipéptidos que se unen a complejos de péptido:mhc
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
CO2018011668A2 (es) Neoantígenos y métodos de su uso
CL2018001953A1 (es) Composición farmacéutica que comprende constructos de anticuerpo biespecíficos
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
MX2020001879A (es) Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
CL2018000307A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CO2018000887A2 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
AR101400A1 (es) Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CL2021002013A1 (es) Biomarcadores para el diagnóstico de cáncer de ovario
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
BR112022008092A2 (pt) Métodos de preparação de uma amostra enriquecida para sequenciamento polipeptídico
CL2020000248A1 (es) Sistemas y métodos para la preparación en tiempo real de una muestra de polipéptidos para el análisis por espectrometría de masas.
PE20201149A1 (es) Anticuerpos de union a hla-a2/wt1
CO2019010164A2 (es) Anticuerpos que se unen a steap-1
CL2021003550A1 (es) Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso solicitudes relacionadas
MX2017005310A (es) Metodos basados en proximidad para seleccion de parejas para ligadura.